A phase I/II study of PT-523 [talotrexin] in patients with refractory leukemia
Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 28 Nov 2013
At a glance
- Drugs Talotrexin (Primary)
- Indications Leukaemia
- Focus Adverse reactions; Therapeutic Use
- 31 May 2012 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
- 31 May 2012 Status changed from suspended to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 07 Nov 2005 New trial record.